The R&D scientific team at Creative Biolabs has designed several efficient strategies to engineer Jurkat for cancer cell self-destruction purposes. By applying our staff's experience and a proven quality system, we are pleased to serve our clients with professionalism and expertise in this field.

Background of Leukemia

Leukemia is a broad term for cancers of the blood cells. The type of leukemia depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. Leukemia occurs most often in adults older than 55, but it is also the most common cancer in children younger than 15. Unlike solid tumors constraint to particular organs, leukemia cells are mobile through the bloodstream and can infiltrate other tissues. Therefore, the management of leukemia becomes complex. Leukemic cancer can be managed through the employment of chemotherapy, immunotherapy and stem cell transplantation. However, side effects of these therapies are associated, such as infection, low blood cell counts, graft versus host diseases and formation of kidney stones. Long-term effects include an increased risk of heart muscle injury, infertility, thyroid dysfunction, chronic fatigue and secondary cancer. Therefore, researchers worldwide are trying to develop effective drugs against leukemia with minimal side effects.

Why Choose Jurkat Cell Line?

The Jurkat cell line is an immortalized T lymphocyte cell line that was established from the peripheral blood of a 14-year boy with acute lymphoblastic leukemia (ALL) at first relapse in 1976. The Jurkat cell line has most often been used as a prototypical T cell line to study multiple events in T cell biology, including a) T cell signaling and b) molecular events in the HIV infection life cycle. In T cell signaling, the Jurkat cell line has been used to model and characterize signaling events in T cell activation, a critical process in an effective adaptive immune response.

Fig.1 The morphology of Jurkat cells. (Guo, et al.; 2019)

Jurkat Engineering Service at Creative Biolabs

Creative Biolabs combines advanced platforms with a team of tenured scientists who are experts in inspiring the lymphangiogenic potentiation of immunotherapy to Turning Cancer Cells Against Themselves. Since Jurkatis is a helpful model in the development of new therapies for ALL. Our scientists have developed several efficient Strategies for engineering Jurkatis for cancer cell self-destruction purposes. Our strategies for engineering cancer cells for self-destruction, include but are not limited to:

• Engineering Cancer Cells with Cytokine Overexpression for Stronger T Cell Activation
• Engineering Cancer Cells with Target-specific Aptamer for Cancer Immunotherapy
• Engineering Cancer Cells with Aptamer-siRNA for Enhanced Antitumor T Cell Immunity
• Engineering Cancer Cells with Synthetic Immunomodulatory Gene Circuits for Cancer Immunotherapy
• Engineering Cancer Cells with Targeted siRNA For Cancer Immunotherapy

What's more, it is important to assess the effect of self-destruction cancer cells. We are proud to launch our custom Self-destruction Assays, including but not limited to:

• Lymphangiogenesis Analysis
• Kinetics Analysis of Overexpressed Cytokine Secretion
• Naïve T Cell Infiltration Analysis
• Frequency Analysis of Antigen-presenting cells (APCs) Subsets in the Draining Lymph Nodes (dLNs)
• T Cell Activation Analysis
• Antigen-specific T Cell Response Analysis
• Determination of the Effect of Self-destruction Cancer Cells on Preexistent Tumor

For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

1. Guo, J.; et al. 3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression. Experimental and Therapeutic Medicine. 2019, 17(3): 1593-600.

For Research Use Only | Not For Clinical Use